Capricor Therapeutics Faces Shareholder Class Action Lawsuit

The complaint centers on allegations that Capricor altered its statistical analysis plan for Deramiocel clinical data without prior FDA agreement. According to the lawsuit, the company failed to disclose that these deviations from the pre-specified plan jeopardized the Biologics License Application, creating a significant risk that the treatment would be rejected due to insufficient evidence of effectiveness. Shareholders contend these omissions rendered the company's public statements materially misleading throughout the specified period, ultimately resulting in financial losses when the discrepancy reached the market.

Brian Schall and David Schwartz of the Los Angeles-based firm are leading the outreach for potential plaintiffs. While the class has not yet received formal certification, affected investors may contact the firm to discuss their legal standing and potential recovery options. Participation as a lead plaintiff remains optional for those seeking to recover damages related to the company’s disclosures.